Popular topics to explore
📊 COMPANIES WITH STRONG RESULTS (NEHA GUPTA SEBI RA)
📊 COMPANIES WITH STRONG RESULTS
1️⃣ Power, Electrical & Energy
POLYCAB • SIEMENS • POWERINDIA • APARINDS • TDPOWERSYS • PREMIERENE • QPOWER
POLYCAB
2️⃣ Automobile & Auto Components
BAJAJ-AUTO • TVSMOTOR • CRAFTSMAN • SJS • ATHERENERG •…
📊 COMPANIES WITH STRONG RESULTS Strong results
📊 COMPANIES WITH STRONG RESULTS 1️⃣ Power, Electrical & Energy POLYCAB • SIEMENS • POWERINDIA • APARINDS • TDPOWERSYS • PREMIERENE • QPOWER 2️⃣ Automobile & Auto Components BAJAJ-AUTO • TVSMOTOR • CRAFTSMAN • SJS • ATHERENERG • GNA • MTA…
Shilpa Medicare SWOT Analysis BY AASHISH
SHILPAMED
Strengths
Strong growth in FY2025-26: Consolidated operating revenue increased to ₹1,538.87 crore, compared with ₹1,286.43 crore in FY2024-25. Consolidated PAT increased to ₹226.20 crore from ₹79.56 crore.
Diversified pharmaceu…
Stocks With Strong Future Guidance — Worth Tracking
• V-Marc
• RR Kabel
• Finolex
• HFCL HFCL
• E2E Networks
• MTAR Technologies
• Syrma SGS
• Netweb Technologies
• Sterlite Technologies
• Sansera Engineering
• Azad Engineering
• Omnitech Engineering
• Dynamatic Technologies
• Aequs
• Ross…
Top Stocks to Watch: Shilpa Medicare, Silver Touch, Rashi Peripherals #shorts
Top Stocks to Watch: Shilpa Medicare, Silver Touch, Rashi Peripherals #shorts SKYGOLD
Top Stocks to Watch: Shilpa Medicare, Silver Touch, Rashi Peripherals #shortsTop Stocks to Watch: Shilpa Medicare, Silver Touch, Rashi Peripherals #shor…
Technical Analysis Shilpa Medicare
The stock SHILPAMED is in a strong uptrend consistently forming higher highs and higher lows over the past few months. The stock has delivered a sharp rally from lower levels and recently witnessed a strong breakout with a high-volume bul…
SHILPA MEDICARE:
CO UNIT APPOINTS DR. UDAY N. HARLE AS THE CHIEF EXECUTIVE OFFICER; MR UDAY'S RECENT ASSIGNMENT WAS AS A CHIEF BUSINESS OFFICER AT ARTEMIS MEDICARE SERVICES.
SHILPAMED
Prabhudas Lilladher Maintains Accumulate on Dr Reddy's
Prabhudas Lilladher maintained Accumulate on Dr Reddy's with a ₹1,400 target cutting FY27 estimates by 5% after the company halted Semaglutide supplies due to API impurity issues. Resolution expected by October November 2026. FY28 estimates…
The Hidden Beneficiaries of India's Laboratory Boom
Everyone is talking about pharma and electronics manufacturing. Few are looking at the laboratories behind them. As India expands into semiconductors, specialty chemicals, pharmaceuticals and defence manufacturing, demand for testing, cali…
Shilpa Medicare Enters Monetisation Phase
Shilpa Medicare spent ₹800 crore on R&D and ₹1,200 crore on capex between FY21-FY25. The payoff is now showing formulation revenue surged 74% to ₹498 crore and biologics revenue more than doubled to ₹151 crore in FY26. Total revenue grew ne…
Shilpa Medicare Commissions Advanced ADC Manufacturing Facility
🧬 SHILPAMED announced that its subsidiary Shilpa Biologicals Private Limited has commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP Manufacturing Facility. The facility is now fully operational, with GMP qualification proto…
Stocks up in price today
GARUDA . – CMP 194.10 | +23.03 | +13.46%
INDOBORAX – CMP 404.85 | +43.60 | +12.07%
SHILPAMED – CMP 582.65 | +34.70 | +6.33%
EMSLIMITED – CMP 432.90 | +24.75 | +6.06%
Overall market is under pressure today, but selective stock-speci…
Strategic Investment Overview: Shilpa Medicare's 30.4% Acquisition in Gate2Brain
SHILPAMED
Executive Summary
Shilpa Medicare Ltd., via its wholly-owned subsidiary Shilpa Biocare Pvt. Ltd., has announced a €7 million strategic investment to acquire a 30.4% equity stake in Spain-based biotechnology firm Gate2Brain. Thi…
SHILPAMED : CO. ENTERS STRATEGIC EQUITY PARTNERSHIP WITH GATE2BRAIN FOR 30.4% STAKE; FOCUS ON ADVANCING BRAIN CANCER THERAPY G2B-002 WITH ORPHAN DRUG DESIGNATION FROM US FDA AND EMA.
SHILPAMED Shilpa Medicare Ltd. reported a strong Q4 FY26 performance
Shilpa Medicare Ltd. reported a strong Q4 FY26 performance with revenue and profitability improving sharply year‑on‑year, driven by oncology formulations and API exports. 📊 Shilpa Medicare Q4 FY26 Results Highlights Metric…
SHILPAMED has secured NCLT Bengaluru Bench approval for its merger with wholly owned subsidiary Shilpa Therapeutics Private Limited. The tribunal order dated February 27, 2026, sets the appointed date as April 1, 2025, with comprehensive r…
Shilpa Biologicals Secures Exclusive Latin America Biosimilar Deal
SHILPAMED's subsidiary, Shilpa Biologicals, has entered a strategic licensing agreement with SteinCares, a specialty healthcare firm in Latin America. This pact grants SteinCares exclusive rights to register, commercialize, and distribute…
SHILPAMED
Shilpa Medicare ; Co Signs Strategic Biotech Partnership with NXI Therapeutics • 🤝 Strategic Collaboration: Shilpa Medicare partners with NXI Therapeutics AG for long-term development and commercial manufacturing support. • 🧬 CDMO Growt…
SHILPAMED has entered into a binding agreement with Switzerland-based NXI Therapeutics AG for development and supply of a New Chemical Entity targeting autoimmune disorders. The partnership includes comprehensive CMC development, GMP clini…
Shilpa Medicare Unit Secures Key USFDA Orphan Drug Tag
SHILPAMED wholly-owned subsidiary, Shilpa Biologicals, in collaboration with mAbTree Biologics AG, has achieved a meaningful regulatory milestone as the U.S. Food and Drug Administration (USFDA) has granted Orphan Drug Designation to their…
